Immunotherapy may lead to long-term remission of metastatic breast cancer
https://www.facingourrisk.org/XRAY/immunotherapy-remission-metastatic-breast-cancer
Full article: https://doi.org/10.1038/s41591-018-0040-8
Metastatic breast cancer is often difficult to treat. In a new approach, called adoptive cell therapy (ACT), a patient’s own T-cells (a type of cancer-fighting immune cells) are collected, multiplied in a lab, and then returned to the patient. The goal is to enhance the patient’s immune system with many more T-cells that recognize and attack metastasized tumor cells. This study reports on a single patient whose metastatic breast cancer is still in remission (no evidence of disease) after more than 22 months following ACT. (8/16/18)
Questions To Ask Your Health Care Provider
- What is the best treatment approach for my type of cancer?
- Am I eligible for the clinical trial covered in this review?
- Am I eligible for any other clinical trials?
- should I have my tumor tested for biomarkers?
- What are the risks and potential benefits of participating in a clinical trial?
Open Clinical Trials
The following studies look at treatment for people with metastatic ER-positive breast cancer.
- NCT04673448: Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation. This study examines the effectiveness of combining the PARP inhibitor niraparib and the immunotherapy dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have advanced breast, pancreatic or ovarian cancer.
- NCT05501886: Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1). This study investigates the efficacy and safety of the selective estrogen receptor degrader (SERD) gedatolisib plus fulvestrant with or without palbociclib to treat patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
- NCT04975308: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3). This study evaluates the efficacy and safety of the selective estrogen receptor degrader (SERD) imlunestrant. Researchers will assess how it works compared to standard hormone therapy and how well it works when combined abemaciclib compared to imlunestrant in participants with breast cancer that is ER-positive and HER2-negative.
- NCT05306340: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer). This study evaluates the efficacy and safety of the selective estrogen receptor degrader (SERD) giredestrant, plus everolimus compared with exemestane plus everolimus in people with estrogen receptor ER-positive, HER2-negative locally advanced or metastatic breast cancer who have had previous treatment with a CDK4/6 inhibitor and hormone therapy.
- NCT03344965: Olaparib Expanded - Treating Metastatic Breast Cancer in People without gBRCA Mutations. This study looks at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation. This study enrolls people with an inherited mutation in PALB2 or an acquired (tumor) mutation in BRCA1 or BRCA2.
- NCT03685331: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR+/HER2-Negative Metastatic Breast Cancer. This study looks at the side effects and best dose of palbociclib when given with olaparib and fulvestrant for people with HR+/HER2-negative mBC who have a BRCA1 or BRCA2 mutation.
- NCT04072952: ARV-471 Alone and in Combination With Palbociclib in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer. This dose escalation study will determine the safety and tolerability of ARV-471 alone and combined with palbociclib in people with ER+/HER2- locally advanced or metastatic breast cancer who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.
- NCT04448886: Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC. This study evaluates the safety and effectiveness of sacituzumab govitecan with or without pembrolizumab for metastatic HR-positive/HER2-negative breast cancer.
- NCT04563507: Combined Immunotherapies in Metastatic ER+ Breast Cancer. in this study, patients receiving standard first-line therapy (letrozole+palbociclib) for metastatic HR+ breast cancer are randomly assigned to also receive stereotactic body radiation therapy (SBRT) for each metastatic lesion.
- NCT04895358: Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Inoperable or Metastatic Breast Cancer (KEYNOTE-B49). The study investigates the safety and efficacy of pembrolizumab plus chemotherapy compared to chemotherapy alone to treat HR+/HER2- locally recurrent inoperable or metastatic breast cancer.
Other clinical trials for people with breast cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.